Farringdon Capital’s Editas Medicine EDIT Stock Holding History

Farringdon Capital’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-16,327	Closed	-$18.9K	–	471
2025 Q1	$18.9K	Buy	+16,327	New	+$24K	0.01%	322

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Farringdon Capital's EDIT Position: Q2 2025 in Review

Farringdon Capital sold out of Editas Medicine (EDIT) in Q2 2025, closing a stake of 16,327 shares — an estimated $18.9K sold.

Farringdon Capital first reported a position in EDIT in Q1 2025 and held it in 1 quarter. The position peaked at $18.9K in Q1 2025. 193 funds tracked by Wall St. Rank hold EDIT as of Q2 2025.

Farringdon Capital reported no remaining Editas Medicine position as of Q2 2025 after selling out during the quarter.
Farringdon Capital sold 16,327 Editas Medicine shares in Q2 2025, an estimated $18.9K.
Farringdon Capital first reported a position in Editas Medicine in Q1 2025 and held it in 1 quarter.
Farringdon Capital's Editas Medicine position peaked at $18.9K in Q1 2025.
193 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2025.

Based on Farringdon Capital's 13F filing for Q2 2025, filed 14 Aug 2025.